8-K: Nektar Therapeutics Wins $90M Verdict Against Eli Lilly

Nektar Therapeutics secured a jury verdict of $90 million in damages against Eli Lilly and Company for breach of the implied covenant of good faith and fair dealing related to their prior collaboration agreement.

Summary

• Nektar Therapeutics has been awarded $90 million in damages plus interest by a jury in its lawsuit against Eli Lilly and Company.
• The lawsuit, filed in August 2023, alleged breach of contract and breach of the implied covenant of good faith and fair dealing concerning the license agreement for rezpegaldesleukin.
• A jury trial commenced on September 8, 2026, and on September 24, 2026, the jury found that Eli Lilly breached the implied covenant of good faith and fair dealing.
• The awarded damages are subject to post-trial proceedings and potential appeals.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a positive development, as the jury found in favor of Nektar Therapeutics and awarded significant damages, although the outcome is subject to post-trial proceedings and potential appeals.

Positives

• Nektar Therapeutics won a jury verdict against Eli Lilly and Company.
• The jury awarded Nektar Therapeutics $90 million in damages.
• The jury found that Eli Lilly breached the implied covenant of good faith and fair dealing in the license agreement.

Negatives

• The jury's verdict is subject to post-trial proceedings.
• Any resulting judgment may be subject to appeal by Eli Lilly and Company.

Risks

• The outcome of post-trial proceedings could alter the jury's verdict.
• Eli Lilly and Company may appeal the jury's decision, leading to further legal uncertainty and costs.

Future Outlook

The future outlook for the $90 million award is contingent on the outcomes of post-trial proceedings and potential appeals by Eli Lilly and Company.

Industry Context

StockSavvy.ai notes that litigation between pharmaceutical companies over collaboration and licensing agreements is not uncommon, often stemming from disputes over development progress, commercialization strategies, or intellectual property rights. This verdict highlights the significant financial implications that can arise from such disputes.

Legal Proceedings

• Nektar Therapeutics v. Eli Lilly & Co., Case No. 3:23-cv-03943-JD: Jury found Eli Lilly breached the implied covenant of good faith and fair dealing and awarded $90 million in damages plus interest. Verdict subject to post-trial proceedings and potential appeal.

Stakeholder Impact

• Shareholders: A positive verdict and potential financial recovery could boost investor confidence and the company's financial position.
• Creditors: The potential influx of $90 million could improve the company's liquidity and ability to meet its financial obligations.

Next Steps

• Post-trial proceedings will take place.
• The District Court will determine the final amount of interest to be awarded.
• Eli Lilly and Company may appeal the jury's verdict.

Key Dates

Recommendation

While the $90 million verdict is a significant positive, the outcome is not final due to post-trial proceedings and potential appeals. This uncertainty warrants a 'hold' recommendation until the legal process is resolved and the financial impact is more certain.

Keywords

breach of contract, intellectual property, litigation, licensing agreement, pharmaceuticals, damages, jury verdict